EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ plus CARBOPLATIN plus ETOPOSIDE VS. CARBOPLATIN plus ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)-MedSci.cn

EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ plus CARBOPLATIN plus ETOPOSIDE VS. CARBOPLATIN plus ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Orfanos, P; Castro, AY; Quach, C

VALUE IN HEALTH, 2019; 22 (): S471

科室
- - 订阅+
  - 更多科室
工具
服务